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The application of membrane bioreactor (MBR) technology was investigated with the aim of evaluating
its potential for cytostatic drug and cytotoxicity bioremoval. The toxicity removal was assessed from bio-
marker test. CP removal of up to 80% was achieved under the operating conditions studied (HRT of 48 h
and a SRT of 50 days). The increase of TMP was associated with an increase of supernatant toxicity as if
fouling led to retention of the toxicity. Peaks of supernatant cytotoxicity were correlated with peaks in
supernatant humic acid contents. It may suggest that molecules with a toxic effect may be adsorbed
or entrapped in humic acids substances. Our study then points out that advances in wastewater treat-
ment using an MBR can provide a suitable process for lowering CP concentrations before discharge into
the aqueous environment. However, a tertiary treatment is necessary if complete elimination of toxicity
is targeted.
1. Introduction
Pharmaceuticals are designed to have biological activity in
humans and may have adverse effects on aquatic organisms. Phar-
maceuticals and other micropollutants in wastewater pose a new
challenge to both wastewater professionals and the pharmaceuti-
cal industry (Larsen et al., 2004). Compounds with a very potent
mechanism of action, such as cytostatic drugs, are of particular
environmental concern, even though consumption rates and ex-
pected concentrations in the environment may be comparatively
low (Buerge et al., 2006; Kümmerer, 2001). The demand for che-
motherapy treatment is increasing by about 10% per year in devel-
oped countries. In addition, cancer incidence is rising and this is
not simply due to a greater proportion of elderly people in the pop-
ulation (Johnson et al., 2008).
The alkylating antineoplastic drug cyclophosphamide (CP) is one
of the oldest known cytostatics and is one of the most frequently
used agents in cancer chemotherapy (Gilard et al., 1994). After
application to patients, the agent is excreted renally and up to
20% of the dose may leave the body unmetabolized. Besides its
cytotoxic effects, CP possesses teratogenic and mutagenic proper-
ties and is a known human carcinogen (Steger-Hartmann et al.,
1997). CP is a prodrug that requires biotransformation to become
cytotoxic (Moore, 1991; Sladek, 1994). It is transformed, via hepatic
and intracellular enzymes, into active alkylating metabolites,
4-hydroxycyclophophosphamide, aldophosphamide, acrolein and
phosphoramide mustard (Joqueviel et al., 1998). Such drugs,
partially transformed or even unchanged, usually enter hospital
effluents via the urine and faeces of patients under medical treat-
ment. Therefore, they are assumed to be environmentally relevant
compounds. As hospital effluents generally reach the municipal
sewage network without any preliminary treatment, hospitals are
an undeniable release source of anticancer agents (Mahnik et al.,
2007). The compounds finally reach the aquatic environment via
hospital or domestic wastewater and wastewater treatment plants
(WWTPs) (Buerge et al., 2006).
CP has been detected in concentrations ranging from 20 ng/L to
4.5 lg/L in hospital sewage and concentrations ranging from 7 to
143 ng/L have also been found in samples from the influent and
the effluent of the communal sewage treatment plant into which
the hospital’s sewage water is discharged (Steger-Hartmann
et al., 1997). CP has been detected in surface waters in Switzerland.
Concentrations ranged from 50 to 170 pg/L and were thus several
orders of magnitude lower than the levels at which acute ecotoxi-
cological effects have been reported in the literature (mg/L range).
However, due to a lack of studies on chronic effects on aquatic
organisms and data on the occurrence and effects of metabolites,
a final risk assessment cannot be made (Buerge et al., 2006).
Theoretically, there are several operational conditions in MBRs
which favour enhanced biotransformation and mineralization of
pharmaceutically active compounds (PhACs) (Clara et al., 2005;
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De Wever et al., 2007). Membrane bioreactors (MBR) usually oper-
ate at high sludge retention times and high concentrations of bio-
mass, allowing an intensification of the biological process by the
implementation of resistant and low-growth biomass (De Wever
et al., 2007). These elements may increase the elimination of pollu-
tants with special characteristics, such as low bio-degradability
and low concentration, like PhACs. Although much research is
being directed towards the study of the removal mechanisms of
micropollutants (Urase and Kikuta, 2005), little attention is being
paid to toxicity removal. In previous papers (Avella et al., 2010;
Delgado Luis et al., 2010b), the influence of CP and its principal
metabolites on microbial behavior as well as on extracellular poly-
meric substances formation in a MBR system were reported. In this
work, the application of membrane bioreactor (MBR) technology is
investigated here with the aim of evaluating its potential for cyto-
toxicity and cytostatic drug bioremoval.
2. Methods
2.1. Pilot-scale experiments
The schematic diagram of a crossflowMBR pilot system is shown
in Fig. 1. TheMBR pilot was inoculated with activated sludge from a
municipal sewage treatment plant (initial dry weight, 3 g/L). Raw
water was composed of domestic water (wastewater treatment
plants, Brax, France, 2000 equivalent-inhabitant) pre-screened to
200 lm and completed with ViandoxÒ (commercial product, soya
bean extract) so as to reach the chemical oxygen demand (COD)
required to achieve high volumetric loading rates (Table 1).
Treatment was operated in aerobic/anoxic conditions. Cyclophos-
phamide (5 lg/L) and its main metabolites (acrolein 2250 ng/L,
phosphoramide mustard 8880 ng/L, 4-ketocyclophosphamide
(Keto CP) 580 ng/L, nitrogen mustard 517 ng/L) were continuously
added to the pilot. Chemicals were supplied by NIOMECH, part of
IIT GmbH (University of Bielefeld, Universitäts str., 25, DE-33615
Bielefeld): D-18845 – 4-ketocyclophosphamide; D-18846 – phos-
phoramide mustard; and D-19990 – nitrogen mustard hydrochlo-
ride, and by SIGMA (St. Quentin Fallavier, France): 01680
acrolein; C0768 cyclophosphamide.
The membrane module was a ceramic tubular MembraloxÒ
(MF) with 0.0055 m2 surface area and pore size 0.1 lm (Pall Exekia,
France). In order to keep complete mixing in the bioreactor, a
Ruston turbine was installed (260 rpm). Dissolved oxygen and pH
in the bioreactor were monitored. The operating conditions of
the MBR during the experiments are given in Table 1. Pressures
were measured at the inlet (Fig. 1, P1), outlet (Fig. 1, P2), and per-
meate side of the membrane (Fig. 1, P3) in order to determine the
transmembrane pressure (TMP). At constant permeate flux, TMP
indicates the extent of membrane fouling and it was calculated
as follows (Eq. (1)):
TMP ¼
P1 þ P2
2
ÿ P3
 
ð1Þ
2.2. Analytical methods
The chemical composition of soluble extracellular polymeric
substances (EPS) was analysed for proteins, humic substances
and polysaccharides. Proteins and humic substances were mea-
sured by the modified Lowry method with bovine serum albumin
and humic acid as standard (Frolund et al., 1995). Polysaccharides
were determined according to the anthrone method with glucose
as standard (Dreywood, 1946).
2.3. Sample extraction and method of CP analysis
The analysis of CP was performed by LC–MS–MS after lyophili-
sation and extraction with dichloromethane.
2.3.1. Extraction
All CP samples were concentrated by a lyophilisation–extrac-
tion procedure. Briefly, 200 lL isophosphamide (0.1 mg/mL) was
added into a 100-mL CP sample as an internal standard. The 100-
mL sample was frozen in 500-mL glass bottles (Quickfit, England)
in a liquid nitrogen bath in a rotation evaporator (Phenomenex,
France) for about 12 min. Then the frozen sample bottle was con-
nected with the lyophiliser (CARLO ERBA, France) over night under
vacuum conditions. After lyophilisation, the sample powder ob-
tained was carefully transferred into a 30-mL glass tube (Scientific,
France). The 10 mL dichloromethane was then added into the
bottle. The bottle was shaken manually for 10 min to completely
dissolve the remaining powder. This operation was repeated two
more times with 5 mL dichloromethane and all the dichlorometh-
ane fractions were brought together in the 30-mL tube. The sample
tube was shaken gently in the shaking bed (Stuart, France) for
30 min to further dissolve CP in the dichloromethane. The simple
was centrifuged for 10 min at 2000 rpm. The dichloromethane
phase was transferred into a 20-mL glass tube with a pipette and
the tube was placed in the evaporator (PIERCE 18780, France) to
be completely dried under a gentle nitrogen stream. These opera-
tions were repeated twice with 5 mL dichloromethane. Finally,
for LC–MS–MS analysis: 100 lL methanol/ammonium formate
buffer (50/50), pH 5.7, was added.
CP recoveries in different water matrices were mostly greater
than 75% and the overall variability of the method was below 8%.
The extracted samples were stored at ÿ80 °C for further analysis.
2.3.2. LC–MS–MS
The LC–MS–MS (LCQ Advantage, Thermo Finnigan) method was
applied for CP confirmation and quantification at lower CP
concentration and in a complex water matrix. The injection volume
was 20 lL. The mobile phase consisted of a gradient of methanol–
ammonium formate buffer CH5NO2 2 mM (pH 5.7) (Fluka) circu-
lated at an isocratic flow rate of 0.20 mL/min (time/methanol/
ammonium formate buffer = 0/20/80 – 9.5/45/55). The column
used was a C18 125 mm/2 mm Nucleosil 100 Å – 5 lm HD main-
tained at a temperature 30 °C. The column was protected by a filter
of 0.5 lm (Frit SS Blk – Cluzeau France). The MS was operated in
the positive electrospray ionisation (ESI+) mode, using multiple
reactions monitoring (MRM). Under ESI+ conditions, acquisitionFig. 1. Membrane bioreactor (MBR) schematic diagram.
was performed by monitoring the following transition 261 > 233
for CP and isophosphamide. The cone voltage and collision energy
for each transition were programmed through the Excalibur acqui-
sition software. The detection limit of the method (LC–MS–MS) for
CP was 10 ng/mL. All solvents (methanol and dichloromethane)
were of HPLC grade from Sigma, France. Ultrapure water was used
as the eluent in liquid chromatography tandemmass spectrometry
(LC/MS/MS).
2.4. Cytotoxicity analyses
Cytotoxicity tests were performed periodically on influent,
supernatant and permeate MBR samples. Fig. 2 shows an example
of this test where the cytotoxicity was evaluated by measuring
either the proliferation (>100% in Fig. 2) or viability (death,
<100% in Fig. 2) of treated cells (in contact with MBR samples,
e.g., in Fig. 2 cells were treated with MBR supernatant samples)
compared to controls (untreated cells without MBR sam-
ples = 100% in Fig. 2) as described previously (Faucet-Marquis
et al., 2008). Tests of cell proliferation or viability were made on
human liver cells (HepG2) because this cell line was most sensitive
to the effects of the products tested. Proliferation or viability was
measured quantitatively by the colorimetric tetrazolium (MTT) as-
say and based on the metabolic activity of viable cells.
3. Results and discussion
The experiments were performed over 160 days in the first
experimental campaign. The three major changes were: day 21,
first day of addition of cyclophosphamide and its principal metab-
olites (CPs) to MBR; day 65, increase of crossflow velocity from 4 to
5 m/s in both reactors; day 114, change of membranes for two new
membranes with similar initial permeability. This was done not
only to reduce the transmembrane pressure but also to determine
whether the increase in TMP in MBR was related to irreversible
membrane fouling or to the physicochemical properties of the
mixed liquor (Delgado Luis et al., 2010a).
The experiments were performed over 223 days in the second
experimental campaign. Day 108 was the first day of addition of
pharmaceutical compounds (CPs) into the MBR. The activated
sludge was exposed over a long period (107 days) (more than 1.5
times the sludge retention time) before the addition of the cocktail.
Thus, we can also assume that the biomass was completely
adapted to the imposed operating conditions before the addition
of pharmaceutical compounds (CPs).
3.1. Cyclophosphamide removal efficiency in MBR
Fig. 3(a) and (b) show CP concentration variations in the influ-
ent, supernatant and permeate during experimental campaign I
and experimental campaign II, respectively. For both campaigns,
it was observed that the CP concentrations in the supernatant
and permeate of the bioreactor were very similar. It can thus be
supposed that there is no retention by the membrane during filtra-
tion, whatever its degree of fouling (Fig. 3). Therefore, it could be
assumed that CP retention by the membrane + gel layer developed
on the surface of the membrane was negligible.
The CP removal efficiencies during both campaigns are shown
in Fig. 4(a). The time axis has been recalculated so that day 0 is
the first day of the cocktail addition. Preliminary investigations
in a simplified test system indicated a low degradability of CP
(Buerge et al., 2006; Kümmerer et al., 1996). Based on the degrada-
tion studies in a laboratory-scale sewage treatment plant and the
analytical findings in sewage water. Steger-Hartmann et al.
(1997) concluded that excreted CP was only poorly degraded dur-
ing its passage through the sewage treatment plant. Even though
some studies (Buerge et al., 2006; Kümmerer et al., 1996) indicate
that CP is not or is only poorly biodegradable, a removal of CP was
observed in our study. Removal of CP started from the beginning of
the experiment (Fig. 4(a)). After 70 days of continuous addition of
the cocktail (CP and its principal metabolites), the CP removal effi-
ciency was up to 80% during both campaigns (Fig. 4(a)) and proved
the ability of the MBR to partially remove cytotoxic compounds.
However, at the end of experimental campaign I, values greater
than 80% removal were achieved, possibly due to a longer period
of adaptation of the micro-organisms to the cocktail of pharmaceu-
tical compounds than in the second campaign (treatment with the
Table 1
Operating conditions of the membrane bioreactor (MBR) during the experiments.
Parameter Experimental
campaign I
Experimental
campaign II
Working volume (L) 20 20
Temperature (°C) 25–32 25–32
pH 7–8 7–8
Average inlet COD (mg COD/L) 2300 1695
Average organic loading rate
(kg CODmÿ3 dÿ1)
1.15 1.27
F/M (kg CPDinlet/kg MLSS/d) at
steady-state
0.14 0.11
Solids retention time (SRT) (d) 50 70
Hydraulic retention time (HRT) (h) 48 32
Aeration cycle 2 min with
aeration/23
without aeration
2 min with
aeration/17
without aeration
Crossflow velocity (m/s) 4–5 4–5
Fig. 2. Cell proliferation or viability variation in cells treated with MBR supernatant samples compared to controls. Experimental campaign I.
cocktail for 2.7 times the sludge retention time during experimen-
tal campaign I and 1.6 times the sludge retention time during
experimental campaign II). The CP removal mechanisms have been
reported previously. Adsorption onto sludge flocs and biodegrada-
tion both affect the overall removal (Delgado et al., 2009). As CP
was present at low concentrations, it could not be used as the pri-
mary source of energy/carbon, so it could be suggested that CP was
cometabolically degraded. In previous studies, other authors have
indicated that cometabolic transformation may be the major re-
moval mechanism of some PhAC compounds in activated sludge
treatment of municipal wastewater (De Wever et al., 2007; Joss
et al., 2005).
Even if a comparison between the results of the two campaigns
is difficult because several variables were changed, not only the
sludge retention time, it appears that a sludge age of 50 days, a
hydraulic retention time of 48 h was sufficient to achieve a re-
moval efficiency of 80%. Nevertheless, the effect of sludge age on
the elimination of some micropollutants has already been studied
(Clara et al., 2005; De Wever et al., 2007; Weiss and Reemtsma,
2008). Weiss and Reemtsma (2008) studied the influence of sludge
age on the elimination of polar micropollutants. In this study, a
slight trend towards improvement of the elimination was observed
by increasing the sludge age from 26 to 37 days, but it remained
statistically insignificant. In addition, they observed that increasing
the sludge age to 102 days seemed adverse to a compound that
was supposed to be degraded by cometabolism. On the other hand,
concerning hydraulic retention time (HRT), previous studies sug-
gest that a minimumHRT is needed for optimal degradation, which
seems to be situated above 5 h (De Wever et al., 2007). Weiss and
Reemtsma (2008) anticipated that the lowest HRT of 7 h was long
enough for trace pollutant removal by MBR and that a further
extension would have only marginal effects on polar pollutant re-
moval. On the other hand, Joss et al. (2005) noted that HRT had
only a minor influence on the removal of pharmaceuticals and fra-
grances, when considering HRTs of 0.7 h for a fixed bed system,
13 h for an MBR and up to 17 h for a CAS. In our studies, the HRTs
were greater than 32 h. Based on previously studies, it could thus
be assumed that a further extension would have only marginal
effects on cyclophosphamide removal.
3.2. Cytotoxic removal efficiency in MBR
In previous work (Delgado Luis et al., 2010b), it was observed
a chemical stress caused by CPs on micro-organism in the MBR.
CPs toxicity could caused a diversion of carbon and/or energy
from growth to adaptive responses and protection (i.e., an in-
creased in extracellular polymeric substances (EPS) concentration
in the biological sludge, especially of soluble substances, mainly
polysaccharides and proteins was observed. The formation of EPS
seamed to be a protection mechanism (Avella et al., 2010)), and
Fig. 3. (a) CP concentration and transmembrane pressure (TMP) variation during experimental campaign I: (N) influent, (s) supernatant, (d) permeate, and (j) TMP. (b) CP
concentration and transmembrane pressure (TMP) variation during experimental campaign II: (N) influent, (s) supernatant, (d) permeate, and (j) TMP.
an inhibition of catabolism and anabolism that can be offset by the
biomass still active under low substrate/biomass condition in the
bioreactor which helped to maintain high overall performance in
the removal of conventional pollution.
As a further investigation to the earlier work, in this work it was
evaluated the MBR potential for CP cytotoxicity bioremoval. Cyto-
toxicity tests were performed on influent, supernatant and perme-
ate MBR samples. Cytotoxicity was evaluated using hepatic cell
culture in optimised conditions, by measurement of either cell pro-
liferation or death as explained in Section 2.4.
Fig. 4(b) shows the cytotoxicity variations in comparison to
control (100% viability) during experimental campaign II. A large
decrease was observed in permeate toxicity compared to the influ-
ent toxicity. Thus, this result proved the ability of the MBR to par-
tially remove the cytotoxicity of CPs. Some small differences were
observed between the supernatant and permeate toxicities in the
MBR during this experimental campaign. It could be assumed that,
during experimental campaign II, the cytotoxicity retention by the
membrane + the gel layer developed on the surface of the mem-
brane was negligible. During this experimental campaign II, the
activated sludge was exposed over a long period (107 days, more
than 1.5 times the sludge retention time) before the addition of
pharmaceutical compounds (CPs). Therefore, the biomass was
completely adapted to the imposed operating conditions before
the addition of pharmaceutical compounds (CPs) and only a few
changes were observed in the evolution of the TMP (figure) and
the soluble extracellular polymeric substance (EPS) concentration
(data no shown) in the MBR. On the other hand, during experimen-
tal campaign I, more changes were observed in the variation of EPS
and the variation of TMP in the MBR. The cytotoxicity removal was
also observed (data not shown), but differences were found be-
tween the supernatant and permeate cytotoxicity measured
(Fig. 5).
In order to establish a link between the cytotoxicity (death or
proliferation) observed in the supernatant and permeate of the
MBR pilot and bioreactor behavior, the cytotoxicity tests compared
to 100% viability of the control in the permeate and in the
supernatant, are represented in Fig. 5(a) and (b), respectively for
experimental campaign I. The variation of transmembrane pressure
during experimental campaign I is also presented. It was observed
(Fig. 5(a)) that the increase in cytotoxicity in the supernatant of
the MBR pilot occurred around the days when transmembrane
pressure increased: in day 64 TMP was 1.35 bars and viability
(proliferation) was above 120%, in day 108 TMP was 1.35 bars
and viability (proliferation) was above 120% and in day 1.45 TMP
was 1.5 and viability (death) was below 80%. Variation in permeate
toxicity (Fig. 5(b), ranged from 92% to 105%) was less pronounced
than in supernatant samples. This means that the fouled state of
the membrane seems to be responsible for the toxicity retention;
it participates in the toxicity concentration in the supernatant
when the membrane is fouled and the concentration decreases
when the membrane is clean or only slightly fouled.
Fig. 6 shows supernatant and permeate MBR pilot cytotoxicity
and the variation of the humic acid concentration during experi-
mental campaign I. The same comparison was attempted with pro-
tein and polysaccharides but without any significant results
(results not shown). Increased cytotoxicity was observed in the
supernatant on days when the concentration of humic acid also in-
creased (Fig. 6(a)). Once again, because the variation in permeate
toxicity (Fig. 6(b), ranged from 92% to 105%) was less pronounced
than in supernatant samples, it was not possible to draw any con-
clusions. Nevertheless, Fig. 6(a) strongly suggested that these toxic
compounds could be adsorbed on humic substances, which are
themselves retained by the membrane and are known to contrib-
ute strongly to membrane fouling in MBR. Previously sorption
Fig. 4. (a) CP removal efficiencies; d, experimental campaign I; and h, experi-
mental campaign II. (b) Cytotoxicity variation compared to control (100% viability).
Experimental campaign II: j, influent; s, supernatant; and d, permeate.
Fig. 5. (a) Supernatant cytotoxicity and transmembrane pressure variation com-
pared to control (100% viability) during experimental campaign I: h, TMP; d,
cytotoxicity. (b) Permeate cytotoxicity and transmembrane pressure variation
compared to control (100% viability) during experimental campaign I: h, TMP; d,
cytotoxicity.
studies (Ra et al., 2008) revealed that some micropollutants (i.e.,
diclofenac) could be sorbed onto suspended particles coated by hu-
mic acid and the corresponding reduction in their aquatic toxicity
(Borcherding and Wolf, 2001). Moreover, in our study, it was pre-
viously observed that, during both campaigns, there was no reten-
tion of the CP alone by the membrane during filtration, whatever
its degree of fouling (Fig. 3). It can be assumed that the toxicity
retention observed was principally due not to CP but to CP metab-
olites, which may be adsorbed on the colloidal phase or flocs. This
is in agreement with previous work reporting that CP is a prodrug
that requires biotransformation to become cytotoxic (Sladek, 1994).
The results of this study prove that advanced wastewater treat-
ment using an MBR provides a suitable process for lowering CP
concentrations before discharge into the aqueous environment.
However, residual toxicity was measured at permeate. Therefore,
a tertiary treatment step is needed. In this way, Wang et al.
(2009) studied the rejection of CP by nanofiltration (NF) and re-
verse osmosis (RO) membranes from ultrapure (Milli-Q) water
and membrane bioreactor (MBR) effluent. The authors showed that
the RO membrane provided excellent rejection (>90%) under all
operating conditions. Conversely, efficiency of CP rejection by NF
membrane was poor: in the range of 20–40% from Milli-Q water
and around 60% from MBR effluent (i.e., membrane fouling and
interactions between the CP and water matrix appeared to contrib-
ute to the higher rejection of CP).
Finally, our study points out that detailed understanding of the
behavior of pharmaceuticals in the wastewater treatment requires
consideration of their microbial metabolites, i.e., the removal of
both parent drug and metabolites toxicity. Moreover, it is also
important to evaluate the toxicity in the total bioreactor matrix (li-
quid-soluble phase, colloidal phases and solid phase) to determine
if toxicity is completely eliminated, or just transferred to another
phase.
The long-term evaluation of membrane bioreactor technology
on an industrial scale for hospital effluent, preferably at the outlet
of an oncology department, or on wastewater from the pharma-
ceutical industry will ultimately clarify industrial-scale membrane
bioreactor potential in the chemical removal of cytotoxic compounds
and their associated toxicity. However, membrane bioreactors
offer two important advantages for the elimination of pharmaceu-
tical compounds from hospital wastewater: (1) the compact design
allows implementation at the hospital site and (2) the possibility of
operation at high sludge ages to adapt the biomass to the micro-
pollutant. In these conditions, the amount of sludge produced is
reduced and the simultaneous elimination of the COD and nitrogen
can be conducted under selected operating conditions. In addition,
if the sludge became toxic when treating hospital wastewater,
treatment by incineration would become relevant. The decrease
in the quantity of sludge to be incinerated would entail a reduction
in operating costs.
4. Conclusion
The analyses performed allow us to draw the following
conclusions:
 CP removal of up to 80% was achieved under a HRT of 48 h and a
SRT of 50 days.
 During experimental campaign I, the increase of TMP was asso-
ciated with an increase of supernatant toxicity. Peaks of super-
natant cytotoxicity corresponded with peaks in supernatant
humic acid contents. It could be suggests that molecules with
a toxic effect may be adsorbed on humic acids substance.
 Despite advanced MBR wastewater treatment for CP and cyto-
toxic removal, a tertiary treatment is necessary for the complete
elimination of cytostatic compound toxicity.
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